Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016073223> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2016073223 endingPage "80" @default.
- W2016073223 startingPage "80" @default.
- W2016073223 abstract "van Dongen CJ, van den Belt AG, Prins MA, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004;(4):CD001100. Q In patients with acute venous thromboembolism (VTE), is fixed dose subcutaneous low molecular weight heparin (LMWH) more effective than adjusted dose unfractionated heparin (UFH) for reducing symptomatic recurrent VTE? Clinical impact ratings IM/Ambulatory care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Haematology ★★★★☆☆☆ ### ![Graphic][1]</img>Data sources: Cochrane Peripheral Vascular Diseases Specialized Register (July 2004), the Cochrane Central Register of Controlled Trials (Issue 3, 2004), LILACS, bibliographies of relevant articles, researchers, and pharmaceutical companies. ### ![Graphic][2]</img>Study selection and assessment: randomised controlled trials (RCTs) that compared fixed dose subcutaneous LMWH with adjusted dose UFH (intravenous or subcutaneous) for initial treatment (usually the first 5–14 d) in patients with acute VTE. After selection, each study was assessed for adequacy of concealment of allocation before randomisation. ### ![Graphic][3]</img>Outcomes: recurrent symptomatic VTE, major haemorrhage, and all cause mortality. 22 RCTs (n = 8867) met the selection criteria. Categories of VTE included symptomatic deep venous … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif" @default.
- W2016073223 created "2016-06-24" @default.
- W2016073223 creator A5032830120 @default.
- W2016073223 date "2005-06-01" @default.
- W2016073223 modified "2023-09-27" @default.
- W2016073223 title "Review: low molecular weight heparin reduces recurrent venous thromboembolism better than unfractionated heparin" @default.
- W2016073223 cites W2041709488 @default.
- W2016073223 cites W2085060329 @default.
- W2016073223 cites W2102988928 @default.
- W2016073223 doi "https://doi.org/10.1136/ebm.10.3.80" @default.
- W2016073223 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15862070" @default.
- W2016073223 hasPublicationYear "2005" @default.
- W2016073223 type Work @default.
- W2016073223 sameAs 2016073223 @default.
- W2016073223 citedByCount "1" @default.
- W2016073223 crossrefType "journal-article" @default.
- W2016073223 hasAuthorship W2016073223A5032830120 @default.
- W2016073223 hasBestOaLocation W20160732231 @default.
- W2016073223 hasConcept C126322002 @default.
- W2016073223 hasConcept C2776884760 @default.
- W2016073223 hasConcept C2777557582 @default.
- W2016073223 hasConcept C2780868729 @default.
- W2016073223 hasConcept C2991741193 @default.
- W2016073223 hasConcept C35785553 @default.
- W2016073223 hasConcept C71924100 @default.
- W2016073223 hasConceptScore W2016073223C126322002 @default.
- W2016073223 hasConceptScore W2016073223C2776884760 @default.
- W2016073223 hasConceptScore W2016073223C2777557582 @default.
- W2016073223 hasConceptScore W2016073223C2780868729 @default.
- W2016073223 hasConceptScore W2016073223C2991741193 @default.
- W2016073223 hasConceptScore W2016073223C35785553 @default.
- W2016073223 hasConceptScore W2016073223C71924100 @default.
- W2016073223 hasIssue "3" @default.
- W2016073223 hasLocation W20160732231 @default.
- W2016073223 hasLocation W20160732232 @default.
- W2016073223 hasOpenAccess W2016073223 @default.
- W2016073223 hasPrimaryLocation W20160732231 @default.
- W2016073223 hasRelatedWork W2008378983 @default.
- W2016073223 hasRelatedWork W2128880450 @default.
- W2016073223 hasRelatedWork W2156616833 @default.
- W2016073223 hasRelatedWork W2280313514 @default.
- W2016073223 hasRelatedWork W2316585033 @default.
- W2016073223 hasRelatedWork W2353652576 @default.
- W2016073223 hasRelatedWork W2417026009 @default.
- W2016073223 hasRelatedWork W2460603014 @default.
- W2016073223 hasRelatedWork W2944498587 @default.
- W2016073223 hasRelatedWork W4241613774 @default.
- W2016073223 hasVolume "10" @default.
- W2016073223 isParatext "false" @default.
- W2016073223 isRetracted "false" @default.
- W2016073223 magId "2016073223" @default.
- W2016073223 workType "article" @default.
!["van Dongen CJ, van den Belt AG, Prins MA, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004;(4):CD001100. Q In patients with acute venous thromboembolism (VTE), is fixed dose subcutaneous low molecular weight heparin (LMWH) more effective than adjusted dose unfractionated heparin (UFH) for reducing symptomatic recurrent VTE? Clinical impact ratings IM/Ambulatory care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Haematology ★★★★☆☆☆ ### ![Graphic][1]</img>Data sources: Cochrane Peripheral Vascular Diseases Specialized Register (July 2004), the Cochrane Central Register of Controlled Trials (Issue 3, 2004), LILACS, bibliographies of relevant articles, researchers, and pharmaceutical companies. ### ![Graphic][2]</img>Study selection and assessment: randomised controlled trials (RCTs) that compared fixed dose subcutaneous LMWH with adjusted dose UFH (intravenous or subcutaneous) for initial treatment (usually the first 5–14 d) in patients with acute VTE. After selection, each study was assessed for adequacy of concealment of allocation before randomisation. ### ![Graphic][3]</img>Outcomes: recurrent symptomatic VTE, major haemorrhage, and all cause mortality. 22 RCTs (n = 8867) met the selection criteria. Categories of VTE included symptomatic deep venous … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif"](?object=%22van%20Dongen%20CJ%2C%20van%20den%20Belt%20AG%2C%20Prins%20MA%2C%20et%20al.%20Fixed%20dose%20subcutaneous%20low%20molecular%20weight%20heparins%20versus%20adjusted%20dose%20unfractionated%20heparin%20for%20venous%20thromboembolism.%20Cochrane%20Database%20Syst%20Rev%202004%3B(4)%3ACD001100.%20Q%20In%20patients%20with%20acute%20venous%20thromboembolism%20(VTE)%2C%20is%20fixed%20dose%20subcutaneous%20low%20molecular%20weight%20heparin%20(LMWH)%20more%20effective%20than%20adjusted%20dose%20unfractionated%20heparin%20(UFH)%20for%20reducing%20symptomatic%20recurrent%20VTE%3F%20Clinical%20impact%20ratings%20IM%2FAmbulatory%20care%20%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%86%E2%98%86%20Internal%20medicine%20%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%86%E2%98%86%20Haematology%20%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%86%E2%98%86%E2%98%86%20%23%23%23%20!%5BGraphic%5D%5B1%5D%3C%2Fimg%3EData%20sources%3A%20Cochrane%20Peripheral%20Vascular%20Diseases%20Specialized%20Register%20(July%202004)%2C%20the%20Cochrane%20Central%20Register%20of%20Controlled%20Trials%20(Issue%203%2C%202004)%2C%20LILACS%2C%20bibliographies%20of%20relevant%20articles%2C%20researchers%2C%20and%20pharmaceutical%20companies.%20%23%23%23%20!%5BGraphic%5D%5B2%5D%3C%2Fimg%3EStudy%20selection%20and%20assessment%3A%20randomised%20controlled%20trials%20(RCTs)%20that%20compared%20fixed%20dose%20subcutaneous%20LMWH%20with%20adjusted%20dose%20UFH%20(intravenous%20or%20subcutaneous)%20for%20initial%20treatment%20(usually%20the%20first%205%E2%80%9314%20d)%20in%20patients%20with%20acute%20VTE.%20After%20selection%2C%20each%20study%20was%20assessed%20for%20adequacy%20of%20concealment%20of%20allocation%20before%20randomisation.%20%23%23%23%20!%5BGraphic%5D%5B3%5D%3C%2Fimg%3EOutcomes%3A%20recurrent%20symptomatic%20VTE%2C%20major%20haemorrhage%2C%20and%20all%20cause%20mortality.%2022%20RCTs%20(n%20%3D%208867)%20met%20the%20selection%20criteria.%20Categories%20of%20VTE%20included%20symptomatic%20deep%20venous%20%E2%80%A6%20%5B1%5D%3A%20%2Fembed%2Finline-graphic-1.gif%20%5B2%5D%3A%20%2Fembed%2Finline-graphic-2.gif%20%5B3%5D%3A%20%2Fembed%2Finline-graphic-3.gif%22){kind=link}